文献速递泌尿生殖与妇科肿瘤放疗

重组人超氧化物歧化酶在宫颈癌根治性同步放化疗中预防和治疗放射性急性直肠损伤的应用:一项多中心、随机、开放标签、前瞻性试验

Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-05-04

这项在中国14个中心开展的3期随机开放标签试验纳入283例局部晚期宫颈癌患者,评估重组人超氧化物歧化酶(rhSOD)灌肠对放射性急性直肠损伤的疗效。结果显示rhSOD灌肠显著降低≥G1和≥G2腹泻天数及≥G2腹泻发生率,并减少止泻药使用,作者认为其安全且可保护直肠黏膜。

要点

  • rhSOD灌肠组≥G1和≥G2腹泻平均天数显著低于对照组(3.5和0.8天 vs 14.8和4.5天,P < .001)。
  • rhSOD灌肠使≥G2腹泻发生率从53.6%降至24.1%,止泻药使用率更低(36.2% vs 55.7%,P < .001)。
  • 3例患者灌肠后感到无法耐受或腹痛,直肠黏膜损伤分级两组差异未达统计学显著(P = .061)。

核心结论

  • 作者认为rhSOD灌肠安全,并显著降低放射性急性直肠损伤的发生率、严重程度和持续时间,保护直肠黏膜。

研究设计与样本

  • 3期、随机、开放标签试验(NCT04819685),2021年6月至2023年8月在中国14个医疗中心开展,所有患者接受同步放化疗。
  • 共283例患者随机分为实验组(n = 141,放化疗期间接受rhSOD灌肠)和对照组(n = 142,不接受灌肠)。
  • 采用不良事件通用术语标准(第5.0版)评估放疗相关副作用,采用维也纳直肠镜评分评估内镜下表现。

主要发现

  • 实验组≥G1和≥G2腹泻平均天数分别为3.5天和0.8天,对照组分别为14.8天和4.5天(P < .001)。
  • 使用rhSOD灌肠后,≥G2腹泻发生率从53.6%降至24.1%。
  • 实验组止泻药使用率为36.2%,对照组为55.7%(P < .001)。
  • 3例患者在rhSOD灌肠后感到无法耐受或腹痛。
  • 实验组放射性急性直肠损伤分级趋向于低于对照组(P = .061)。

关键数值与推荐

  • 主要终点为同步放化疗期间≥G1腹泻的发生率和持续时间。
  • 次要终点包括≥G2和≥G3腹泻的发生率和持续时间、≥G1和≥G2腹泻持续至少3天的发生率、内镜评估的直肠黏膜放疗损伤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 实验组直肠黏膜损伤分级趋向于低于对照组,但差异未达统计学显著(P = .061)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate the efficacy of recombinant human superoxide dismutase (rhSOD) enemas in radiation-induced acute rectal injury (RARI) in patients with locally advanced cervical cancer. METHODS AND MATERIALS: In this phase 3, randomized, open-label trial (NCT04819685) conducted across 14 medical centers in China from June 2021 to August 2023, all patients received concurrent chemoradiation therapy (CCRT). The experimental group was treated with a rhSOD enema during chemoradiation therapy, and the control group had no enema. The Common Terminology Criteria for Adverse Events (version 5.0) was used to evaluate radiation therapy-induced side effects. Endoscopic appearance was assessed using the Vienna Rectoscopy Score. The primary endpoint in the acute phase was the occurrence rate and duration of grade ≥1 (≥G1) diarrhea during CCRT. Secondary endpoints included the occurrence rate and duration of ≥G2 and ≥G3 diarrhea, ≥G1 and ≥G2 diarrhea lasting at least 3 days, and damage to the rectal mucosa due to radiation therapy measured by endoscopy. RESULTS: Two hundred and eighty-three patients were randomly divided into the experimental (n = 141) or control group (n = 142). The mean number of ≥G1 and ≥G2 diarrhea days were significantly lower in the experimental group than in the control group (3.5 and 0.8 days vs 14.8 and 4.5 days, respectively; P < .001). The incidence of ≥G2 diarrhea decreased from 53.6% to 24.1% when rhSOD enemas were used. Use of antidiarrheals was lower in the experimental group (36.2% vs 55.7%, P < .001). Three patients felt intolerable or abdominal pain after rhSOD enema. RARI grades in the experimental group tended to be lower than those in the control group (P = .061). Logistic regression analysis revealed that rhSOD enema was associated with a lower occurrence rate of ≥G1/2 diarrhea for at least 3 days (P < .001). CONCLUSIONS: The results of this study suggest that rhSOD enema is safe and significantly reduces the incidence, severity, and duration of RARI, protecting the rectal mucosa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhu J, Li X, Huang M, et al. Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38705489. doi:10.1016/j.ijrobp.2024.04.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。